Form 4: Zeo ScientifiX Director Charles Luther Bretz Reports Stock Option Grants

Director Charles Luther Bretz reports receiving two grants of stock options for Zeo ScientifiX, Inc.

Summary

• Charles Luther Bretz, a director of Zeo ScientifiX, Inc., reported the grant of stock options.
• On May 8, 2025, Bretz received two grants of stock options, each for 5,000 shares of common stock.
• The exercise price for both option grants is $2.86 per share.
• One grant of 5,000 shares vested immediately on the grant date.
• The second grant of 5,000 shares vested as to 2,000 shares immediately, with the remaining 3,000 shares vesting on September 23, 2025.
• Both option grants expire on May 8, 2030.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction (stock option grant) without any indication of positive or negative implications for the company's performance.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.

Industry Context

Stock option grants are a common form of executive compensation in the technology and biotechnology industries, used to incentivize performance and align management interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in growth-oriented sectors like Zeo ScientifiX's industry.
• The vesting schedules and exercise prices are generally benchmarked against industry peers to ensure competitiveness and alignment with performance goals.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options extensively as part of their executive compensation plans.

Stakeholder Impact

• The stock option grants could potentially dilute existing shareholders if the options are exercised in the future.

Key Dates

Keywords

stock options, director, ZEOX, Zeo ScientifiX, Form 4, beneficial ownership, equity incentive plan